Posted on 23/11/2009 in Pharmacy Supplier News Dr Reddy's has revealed its financial results for the quarter ended September 30th 2009, which show that its revenues rose by 14 per cent during the period.
Consolidated revenues at the firm reached $382 million (231 million pounds) during the timeframe, compared to $336 million in the correlating quarter of the last financial year.
This is something Dr Reddy's attributes to the success of its global generics business.
Additionally, the results show that revenues from the firm's Pharmaceutical Services & Active Ingredients divisions rose by 11 per cent to $112 million during the second financial quarter of 2010, compared to $100 million in the second quarter of 2009.
During this timeframe, the organisation released a total of 39 new generic products and filed 24 new product registrations globally.
Last month, Bloomberg reported that Dr Reddy's share prices soared to their highest levels since 1991 after rumours that the firm was to be acquired by GlaxoSmithKline.
Other news stories from 23/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
